Stryker Corporation $SYK Shares Acquired by Noesis Capital Mangement Corp

Noesis Capital Mangement Corp raised its holdings in Stryker Corporation (NYSE:SYK) by 36.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 104,945 shares of the medical technology company’s stock after acquiring an additional 27,938 shares during the period. Stryker comprises 3.4% of Noesis Capital Mangement Corp’s holdings, making the stock its 8th biggest holding. Noesis Capital Mangement Corp’s holdings in Stryker were worth $28,901,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. State Street Corp lifted its stake in shares of Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after acquiring an additional 183,400 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after acquiring an additional 45,478 shares in the last quarter. Bank of America Corp DE bought a new stake in Stryker during the 2nd quarter worth $1,404,284,000. Royal Bank of Canada grew its position in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after acquiring an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Stryker by 21.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after purchasing an additional 481,175 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the company. Citizens Jmp dropped their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Stifel Nicolaus lowered their price objective on Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. TD Cowen dropped their price objective on shares of Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a report on Tuesday, September 22nd. Finally, Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $369.00.

Stryker Trading Down 0.2%

NYSE SYK opened at $306.50 on Tuesday. The business’s 50-day moving average price is $295.95 and its two-hundred day moving average price is $326.09. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The firm has a market capitalization of $117.56 billion, a PE ratio of 31.76, a price-to-earnings-growth ratio of 1.98 and a beta of 0.78. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts expect that Stryker Corporation will post 14.93 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.